The small molecule inhibitors of some biogenic enzymes are effective for gliomas

A paper published in the Journal of Cancer Research lists the results of studies on gliomas: 1) identification of biogenic enzymes associated with gliomas; 2) a mechanism for the regulation of such enzymes; 3) by using a mouse model of gliomas, it is shown that the small molecule inhibitors they develop are effective for gliomas. More research involving recombinant rat proteins should be conducted.

Such GA11 inhibitors retain a core structure similar to that of natural inhibitors of biological enzymes; however, such inhibitors have been modified to allow them to pass through the blood-brain barrier.

"In principle, these features make GA11 a candidate for treatment of gliomas," Dr. Ichiro Nakano said.

Nakano is a professor of neurosurgery at the University of Alabama at Birmingham, and he and other researchers are further pre-clinical evaluation of GA11 and its analogues.

"Polymorphic glioblastoma (GBM) is a class of highly lethal tumors. Over the past 30 years, little progress has been made to increase the average survival of patients from five months to 15 to 16 months," Nakano said.

GBM tumors are a class of mixed cell tumors. A small amount of gliomas stem cells induce GBM tumorigenicity, so these stem cells become the primary goal of treatment. Nakano and colleagues infer that determining the regulatory mechanism of bone marrow mesenchymal stem cells activity may develop new and effective treatments. Flarebio offers good-quality recombinant proteins and antibodies like PODXL Monoclonal Antibody.